The Rising Challenge of Antimicrobial Resistance in Gonorrhoea

The World Health Organization (WHO) has issued a stark warning: gonorrhoea, a common sexually transmitted infection (STI), is exhibiting increasing resistance to antibiotics. This trend, documented in the WHO’s latest report, poses a notable threat to public health globally. The report underscores the urgent need for strengthened surveillance systems, improved diagnostic capabilities, and equitable access to new treatments.

The release of this data coincides with World Antimicrobial Resistance (AMR) Awareness Week, emphasizing the broader crisis of drug-resistant infections and the need for coordinated global action. AMR occurs when microorganisms like bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines designed to kill them.

EGASP: Tracking the Spread of Resistance

The WHO’s Enhanced Gonococcal Antimicrobial surveillance Program (EGASP), launched in 2015, is central to monitoring this issue. EGASP collects crucial laboratory and clinical data from sentinel sites worldwide.This data is used to track antimicrobial resistance (AMR) patterns and inform evidence-based treatment guidelines. As of November 2025, EGASP includes data from over 80 countries, providing a comprehensive picture of the global resistance landscape.

Dr. Tereza Kasaeva, Director of the WHO Department for HIV, TB, Hepatitis & STIs, stated, “This global effort is essential to tracking, preventing, and responding to drug-resistant gonorrhoea and to protecting public health worldwide.” The WHO is urging all countries to address the rising levels of resistance and prioritize resources for STI control programs.

Past Trends in Gonorrhoea Resistance

gonorrhoea’s ability to develop resistance to antibiotics is not new. Historically, the infection has overcome treatments like penicillin, tetracycline, and ciprofloxacin. Currently, ceftriaxone, frequently enough used in combination with azithromycin, remains a recommended first-line treatment in many parts of the world.However,resistance to ceftriaxone is increasing,raising concerns about a future where effective treatment options are severely limited.